We recently published Jim Cramer Discusses These 10 Stocks & AI-Led Disinflation. Abbott Laboratories (NYSE:ABT) is one of the stocks Jim Cramer recently discussed. Abbott Laboratories (NYSE:ABT) is a ...

Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

Abbott Laboratories (NYSE:ABT) stock drops as the company reported mixed Q2 2025 results and sets its Q3 guidance below ...

Q2 2025 Earnings Call Transcript July 17, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...

Investing.com -- Jefferies upgraded Abbott Laboratories (NYSE: ABT) to Buy from Hold, calling the market reaction to the ...

Abbott Laboratories, which makes the popular BinaxNow COVID-19 tests, expects significantly fewer sales of its COVID-19 tests in the fourth quarter compared with the rest of the year.

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Abbott Laboratories’ Debt totaled $15 Bil at the end of the latest quarter, while its market capitalization stands at $233 ...

The healthcare-products maker trimmed and narrowed its guidance for the year while reporting strong profit and sales gains in the second quarter.

Abbott Laboratories closed 12.43% short of its 52-week high of $141.23, which the company reached on March 4th.